Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Number of Flu Patients Tanks to 1/1,000th in January vs Previous 5-Year Average: Survey
February 16, 2021
- Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
February 15, 2021
- Kringle, Keio Univ. Sign Research Pact on HGF Therapy for Spinal Cord Injury
February 15, 2021
- JCR’s Hurler Syndrome Drug Gets Orphan Status in US
February 15, 2021
- Sumitomo Dainippon Cuts Operating Profit Outlook on Napabucasin Flop
February 15, 2021
- JCR Pharma’s JR-141 Gets FDA’s Fast-Track Status
February 12, 2021
- Takeda Files Its 1st Cell Therapy, Darvadstrocel, in Japan
February 12, 2021
- Japan Trial Now Underway for Gene Therapy Luxturna; Eyes Riveted on Its Price Tag
February 12, 2021
- Kobayashi Kako Chief to Resign over Drug Mix-Up, Lousy Manufacturing and Cover-Ups
February 10, 2021
- Chugai to Discuss Filing of Actemra for COVID-19 with Japanese Regulators
February 10, 2021
- Keytruda Top-Seller for 6 Months on End: Encise
February 10, 2021
- Napabucasin Fails in PIII for Colorectal Cancer: Sumitomo Dainippon
February 10, 2021
- Japan Ethical Drug Sales Down 3.9% in December: Crecon
February 9, 2021
- Rakuten Medical’s Photoimmunotherapy Now Available in Japan
February 9, 2021
- 7 Japan Drug Majors See 2.7% Revenue Fall in FY2020, COVID-19 Forces Cuts on Guidance: Jiho Tally
February 8, 2021
- 1st Oral GLP Agent Hits Japan Shelves
February 8, 2021
- Chugai COO Okuda to Become CEO, Kosaka to Stay as Chairman
February 8, 2021
- Chugai Targets 1 Global Product Launch Each Year: New Growth Strategy
February 8, 2021
- Kyowa Kirin Aims for CAGR of 10% towards 500 Billion Yen Target by 2025: New Biz Plan
February 8, 2021
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…